Precision Announces 3-Year Pre-clinical Study Results Showing Long-term Durability and Safety of ARCUS In Vivo Gene Editing to Cut LDL Cholesterol Levels in Nonhuman Primates

NEXT STORY
Pfizer and BioNTech Submit COVID-19 Vaccine Stability Data at Standard Freezer Temperature to the U.S. FDA
PREV STORY
Worldwide Dried Blood Spot Collection Cards Industry to 2027 – Increasing Demand in Several Applications Presents Opportunities
Subscribe now to PM360
Get in touch with PM360 Experts On Call

Experts on Call

Ads

You May Also Like

PDS Biotechnology to Present Recent Phase 2 Human Clinical Data and On-Going Oncology Programs at Investor Conferences

author_avatar
NASDAQ Market News

AzurRx BioPharma To Present Interim Phase 2 Clinical Study Data for MS1819-SD, in combination with standard PERT for Cystic Fibrosis Patients with Severe Exocrine Pancreatic Insufficiency, at Biotech Showcase 2020 Conference (January 13) in San Francisco

author_avatar
NASDAQ Market News

Roche reports very strong performance in the first half of 2019 – Outlook raised

author_avatar
NASDAQ Market News